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Background: Homeopathic drug proving is a basic concept in homeopathy. This study aimed to record symptoms
produced by a homeopathic drug compared with placebo.
Methods: This multicentre, randomised, double-blind, placebo-controlled phase 1 trial consisted of a 7-day run-in
period, a 5-day intervention period and a 16-day post-intervention observation period. Subjects, investigators and
statisticians were blinded for intervention groups and identity of the homeopathic drug. Subjects in the
intervention group received Okoubaka aubrevillei (potency C12) and subjects in the placebo group received the
optically identical sucrose globules. Dosage in both groups was five globules taken five times per day over a
maximum period of 5 days. Subjects documented the symptoms they experienced in a semistructured online diary.
The primary outcome parameter was the number of characteristic proving symptoms compared with placebo after
a period of 3 weeks. Characteristic symptoms were categorised using content analysis. Secondary outcome
parameters were the qualitative differences in profiles of characteristic and proving symptoms and the total
number of all proving symptoms. The number of symptoms was quantitatively analysed on an intention-to-treat
basis using analyses of covariance with the subject’s expectation and baseline values as covariates.
Results: Thirty-one subjects were included (19 Okoubaka and 12 placebo). Data for 29 participants could be
analysed. No significant differences in number of characteristic symptoms in both groups were observed between
Okoubaka (mean ± standard deviation 5.4 ± 6.0) and placebo (4.9 ± 5.6). The odds ratio for observation of a
characteristic symptom was 1.11 (95% confidence interval 0.4 to 3.05, P = 0.843). Females and subjects expecting a
higher number of symptoms at baseline or feeling more sensitive to homeopathic drugs experienced more
characteristic symptoms regardless of allocation. The qualitative analysis showed an inter-coder reliability of 0.69
(95% confidence interval 0.62 to 0.76). The qualitative comparison of symptom profiles was inconclusive.
Conclusions: Combined results of qualitative and quantitative methods did not result in a significant difference of
characteristic proving symptoms between O. aubrevillei C12 and placebo. The qualitative comparison of the
symptom profiles leaves some open questions. The nocebo effect might be a plausible explanation for most of the
phenomena observed in this trial.
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Homeopathic drug proving (HDP) trials, also known as
homeopathic pathogenetic trials, are at the foundation
of homeopathy and have been conducted for more than
200 years [1-4]. In addition to exposing the toxic effects
of the drug and clinical experience, HDPs serve as a key
source of information for the homeopathic Materia
Medica. The purpose of such trials is to test nontoxic
levels of a specific substance in healthy volunteers to de-
termine the symptoms this substance stimulates and the
types of individuals who may be sensitive to it. The pro-
file of symptoms recorded in an HDP by a group of
healthy volunteers serves as a basis for information to
find indicators of the drug in sick patients. In HDP, the
drug under investigation is administered and the individ-
ual response of every volunteer to the application of the
substance is described. According to the law of similars,
the substance is then used to treat patients with similar
symptoms. The clinical experience subsequently shapes
the homeopathic drug profile. For 200 years HDPs have
been conducted by homeopathic practitioners in the trad-
itional qualitative and explorative HDP design that was
described in Hahnemann’s nineteenth-century Organon
der Heilkunst [5] and other homeopathic classics. In re-
cent years the need to adapt to modern research designs
has been realised and an innovative new study method-
ology for HDP has been developed and tested [6-11].
Within this study we developed a study design meth-
odology and a study protocol that fulfils the criteria of
the Good Clinical Practice, Declaration of Helsinki and
German drug regulations and also tests its applicability
and feasibility in practice [12]. German drug regulation
authorities classified this HDP as a phase 1 trial, which
can be misleading and has been discussed as controver-
sial [12].
‘Characteristic symptom’ is a very important homeo-
pathic concept to identify the precise homeopathic drug
action in homeopathic provings and to find the right
homeopathic drug for a patient according to the law ofTable 1 Criteria for proving symptoms and characteristic sym
Criteria for proving symptoms
• New symptoms: the symptom is unfamiliar and has not been observed
within the last year or during the run-in period
• Study participant or study physician classifies the symptom as new or
unusual
• The study physician classifies the symptom as new in his final
evaluation
• A strong aggravation or modification of present (familiar) symptoms
• Present familiar symptoms that have disappeared during the proving
(cure)similars (Organon der Heilkunst § 153 [5]). Generally, it
is considered that a good homeopathic prescription
matches the characteristic symptoms of a patient/disease
with the characteristic symptoms of a homeopathic drug
as derived from a HDP. Homeopaths categorise symp-
toms as characteristic when they show a high degree of
individualising signs. In homeopathy it is believed that
the characteristic symptoms in a HDP are specific for
the homeopathic action of a drug. Categorising symp-
toms into characteristic and noncharacteristic is an
essential part of homeopathic case-taking and analysis.
For a further definition of characteristic symptoms, refer
to Table 1. The primary aim of the study was to determine
whether the homeopathic drug Okoubaka aubrevillei of
potency C12 provokes more characteristic homeopathic
proving symptoms after 3 weeks compared with a placebo
in healthy volunteers.
Secondary aims were to develop and to test a qualita-
tive analysis methodology on which to base a definition
for drug-specific (characteristic) symptoms and to com-
pile a profile of characteristic homeopathic proving




The HDP trial was conducted as a multicentre,
randomised, double-blind, placebo-controlled phase 1
trial. Subjects and investigators were not only blinded to
the group allocation process but also to the identity of
the drug.
Subjects
Volunteer medical students or medical doctors were
invited to take part in the trial by the investigators via
email or telephone.
Subjects were included if they fulfilled the following
criteria: medical doctors or medical students, over 18
years of age, not currently being treated for any acute orptoms
Criteria for characteristic symptoms
Characteristic symptoms are defined as proving symptoms with a
strongly individualistic character:
• Symptoms affecting the whole organism of one or more study
participant
• Symptoms affecting different organs or organ systems of one or
more study participant
• Symptoms accompanying a variety of other symptoms
• Symptoms that occur during the trial that appear strange, peculiar
or unique to one or more study participants
• Familiar symptoms from the past or present that have been cured
or strongly alleviated
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informed consent.
The following exclusion criteria applied: pregnant
women or nursing mothers were excluded, as was any-
one who had received homeopathic treatment over the
previous 6 weeks, anyone who had participated in an-
other clinical trial during the last 6 months, anyone with
a personal or professional dependence on the study
physician or sponsor, as well as anyone who had been
placed in hospital or another institution by authorities
or decree.
Investigators
The investigators were homeopathic medical doctors
with knowledge of HDP and had at least 3 years’ prac-
tical experience in homeopathic therapy. All investiga-
tors were required to have completed a 2-day certified
and standardised investigator training programme.
Ethics and consent
All subjects provided written informed consent prior to
the inclusion. Information about the trial was provided
during one-on-one interviews with the help of a written
brochure for study subjects. The study was approved by
the Berlin Ethics Committee (Landesamt für Gesundheit
und Soziales Berlin) on 17 August 2009 (Reference: ZS
EK 15, 287/09). The trial was registered under
ClinicalTrials.gov: Identifier NCT01061229.
Procedures
The study consisted of a 7-day run-in period (baseline
observation), a 5-day intervention period, followed by a
16-day follow-up observational period.
Each study centre consisted of one investigator who
supervised between one and three subjects. After having
given informed consent, subjects received an initial
physical examination, a full-length homeopathic inter-
view of 60 to 120 minutes’ duration and a short instruc-
tion on formal and technical aspects of documentation.
The following items were assessed at baseline: age, sex,
education (medical student or doctor), history of former
chronic disease, former homeopathic treatment, and
former participation in an HDP. Subjects and investiga-
tors were also asked to rate their expectations about the
subjects’ responsiveness to homeopathic drugs as ordi-
nals with four levels, because the authors presume that
this could be a factor related to the outcome.
Questions to subject: (A) ’How would you estimate
your sensitivity to homeopathic remedies in general?’ –
possible answers: strong reaction / reaction / slight reac-
tion / no reaction; and (B) ’How do you expect to react
to the homeopathic drug?’ – answers: a very high num-
ber of symptoms / many symptoms / low number of
symptoms / no symptoms.Questions to investigators: (A) ’How would you esti-
mate your subject’s sensitivity to homeopathic remedies
in general?’ – response options same as above; and (B)
’What is your expectation about your subject’s reaction
to the homeopathic drug?’ – response options same as
above.
After starting the trial, subjects were required to docu-
ment any new or uncommon symptoms in a semi-
structured trial diary daily (head-to-feet structure to be
filled in with free text) accessed through a secure Inter-
net connection. The subjects were supervised by the
investigators via telephone in short intervals, as is com-
mon in HDP.
Randomisation and treatment allocation
The random list (block randomisation stratified by
centre/investigator) was based on the ‘ranuni’ random
number generator of the SAS/STATW software, SAS
Institute Inc., Cary, NC, US. Both the centres and subjects
were coded by simple numbers unidentifiable by subjects,
investigators and other persons. The randomised list was
sent to the Charité central pharmacy, which prepared
sealed, sequentially numbered boxes containing the study
medication and sent them to the centres. When a subject
agreed to participate, the investigator opened the lowest
numbered box and gave him/her the study medication.
Each centre kept a log file of all randomised subjects.
Intervention
Subjects in the intervention group were instructed to
take five globules of the trial drug (potency C12), five
times per day for a maximum of 5 days (5 × 5 × 5). The
study medication was obtained from DHU (Karlsruhe,
Germany), produced according to the Hahnemannian
method [13]. Subjects were asked to stop taking the
medication, in agreement with their investigator, if they
experienced any of a predefined set of proving symp-
toms (see Table 1). Placebo consisted of pure sucrose
globules (DHU) that were not potentiated nor impreg-
nated with alcohol. The administration scheme in the
placebo control group was identical to that of the inter-
vention group.
Outcome parameters
In our trial we decided to base our hypothesis testing
strongly on homeopathic rules and decided to use the pe-
culiar, strange and strongly individual (= characteristic)
symptoms as the primary outcome parameter.
The primary outcome parameter was the number of
characteristic proving symptoms per subject, derived
from the qualitative data analysis of the homeopathic
proving drug compared with placebo within 3 weeks
after the initial dose of the drug or the placebo is
Figure 1 Flowchart of participants.
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given in Table 1.
Secondary outcome parameters were the total number
of proving symptoms, irrespective of whether they were
characteristic or not, and the number of serious adverse
events.
Qualitative differences in the profiles of characteristic
proving symptoms from the homeopathic drug and the
placebo were compared and the inter-coder reliability of
the qualitative evaluation of characteristic proving symp-
toms was calculated.
Sample size calculation
In this study, an unpaired t test with a two-sided level of
5% has a power of 80% to detect a group difference of
20 ± 4 versus 15 ± 4 (mean ± standard deviation) charac-
teristic proving symptoms. Assuming a dropout rate of
20%, 24 subjects have to be available for analysis. As the
sample size calculation was based on an estimation of
experts, we decided to include up to 30 subjects.
Analysis
The qualitative analysis of the textual data of the diaries
was carried out by two experienced homeopathic doc-
tors using content analysis [14]. Homeopathic definitions
for proving symptoms and characteristic symptoms
(Table 1) served as predefined categories for the deduct-
ive coding processes. For more details and discussion of
the analysis process we refer to the publication of our
study protocol [12]. The quantitative analysis was carried
out by a statistician.
Our main hypotheses to test were as follows:
H0: There is no difference between the number of
characteristic symptoms provoked by a homeo-
pathic drug in the potency C12 compared with
placebo.
H1: There is a difference between the number of
characteristic symptoms provoked by a homeo-
pathic drug in the potency C12 compared with
placebo.
The main outcome was analysed on an intention-to
-treat basis by univariate analyses of covariance, which
includes the group (two levels), subject’s expectations
(ordinal with four levels) and the respective baseline
value (linear) as covariates. From these models we esti-
mated the baseline-adjusted treatment effect and its 95%
confidence interval (CI). The reported P value was based
on a two-sided t test within this model, and P <0.05 was
considered significant. Missing values were multiply im-
puted according to Rubin’s suggestions [15]. In detail, 20
multiple copies of the original dataset were generated,
replacing missing values by a randomly generated valueaccording to the MCMC algorithm. Each copy was
analysed as a complete dataset with the abovementioned
analyses of covariance model and the results combined
appropriately. Sensitivity analyses included some exten-
sions of the statistical model, in this way modelling the
centre as a random factor and adding the centre’s
expectation (ordinal with four levels) as an additional
fixed factor.
Analyses of the secondary outcome parameters relied
on the same statistical models, hereby replacing the
baseline value of the main outcome parameters by the
baseline value of the parameter under consideration. All
analyses were performed using SAS/STATW.
Results
We included 31 subjects who were supervised by 13
investigators. The flow of participants through the trial
is illustrated as a flowchart in Figure 1. The diaries of 29
participants could be analysed and evaluated. One par-
ticipant withdrew her participation prior to the start of
the trial due to acute disease. Another participant had to
be excluded as she took additional homeopathic medica-
tion during the intervention. There were baseline differ-
ences between both groups (Table 2): subjects in the
Okoubaka group were on average 7 years younger than
those in the placebo group, whereas the placebo group
had a higher percentage of medical doctors compared
with the Okoubaka group. All subjects in the placebo
group estimated that they were sensitive or highly sensi-
tive to homeopathic drugs, whereas this was only the
case in 55% of subjects in the Okoubaka group. One-
third (36%) of the subjects in the placebo group







Age (± standard deviation) 41.1 (± 8.9) 33.9 (± 8.5)
Female (%) 8 (73) 11 (61)
Medical doctors (%) 10 (91) 13 (72)
Medical students (%) 0 (0) 5 (28)
Disease history
Past chronic disease (%) 6 (54) 9 (50)
Present chronic disease (%) 7 (64) 12 (67)
Experiences
Experiences in participation in past HDP (%) 2 (18) 3 (16)
Estimation of sensitivity to homeopathic drugs
Sensitive or highly sensitive
• Subjects’ estimation (%) 11 (100) 10 (55)
• Investigators’ estimation (%) 10 (91) 15 (73)
Expectation about reaction to homeopathic drug
Observation of very high numbers / many symptoms
• Subjects’ estimation (%) 4 (36) 2 (11)
• Investigators’ estimation (%) 9 (82) 10 (56)
HDP, homeopathic drug proving. aOne subject was a pharmacist.
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toms compared with only 11% in the Okoubaka group.
No significant differences in the number of characteris-
tic symptoms in both groups were observed. Adjusted
means of characteristic symptoms in the Okoubaka group
were 5.4 (± 6.0) and in the placebo group 4.9 (± 5.6). The
group difference calculated as the odds ratio for observa-
tion of a characteristic symptom was 1.11 (95% CI = 0.4 to
3.05), which is not significant (P = 0.843, Table 3).
No significant differences in the number of proving
symptoms in both groups were observed. Subjects in
the Okoubaka group experienced 8.8 (± 9.6) proving
symptoms versus 9.6 (± 10.6) in the control group, the
group difference (odds ratio for observation of a prov-
ing symptom 1.04, 05% CI = 0.33 to 3.29) was not sig-
nificant (P = 0.951, Table 3).
An analysis of subgroups for sex shows a difference be-
tween male and female subjects regardless of group alloca-
tion. A mean of 2.3 (placebo: ± 3.2; Okoubaka: ± 2.8)
characteristic symptoms were observed in men of both
groups, while in women the mean number of characteris-
tic symptoms was much larger with 5.9 (± 6.2) symptoms
for placebo and 7.5 (± 6.7) for Okoubaka (Table 3). Gener-
ally, subjects expecting a higher number of symptoms at
baseline or who felt more sensitive to homeopathic drugs
experienced more characteristic symptoms, regardless of
group allocation (Table 3).The two homeopaths who independently coded the
text of the diaries for characteristic symptoms reached
an inter-coder reliability (Cohen’s kappa) of 0.69 (95%
CI = 0.62 to 0.76; before reaching consensus on the
symptom categorisation in a final discussion). Table 4
shows the qualitative symptom profiles of Okoubaka and
placebo for comparison. In the third row, only symp-
toms of Okoubaka that were not observed under placebo
are listed. These can be compared with a former HDP of
O. aubrevillei and the clinical homeopathic use in the
fourth and fifth rows. The qualitative analysis showed
characteristic (highly individual, specific or peculiar)
symptoms in both groups. In summary, frequently ob-
served overlapping characteristic symptoms between
Okoubaka and placebo were difficulties in concentration,
tiredness, headaches, pain in extremities and gastrointes-
tinal disturbances. In the Okoubaka group alone there
were general feelings of dryness and burning in multiple
parts of the body and feelings of soreness in mucosal
membranes and muscles. One subject in the Okoubaka
group developed a chronic pharyngitis with vesicular
eruptions in the intervention period that lasted for
6 months after the trial. Another subject in the
Okoubaka group developed multiple warts. In the pla-
cebo group, no symptoms with objective physical and
stable pathological changes were observed. Overall there
is a high degree of concordance between Okoubaka and
placebo and many of these symptoms also show similar-
ities to the symptoms of a former proving and the clin-
ical profile.Discussion
In both groups, characteristic symptoms were identified
by the qualitative analyses. Statistically significant group
differences in the numbers of characteristic symptoms
could not be detected. A subgroup analysis showed that
women and individuals expecting to be sensitive to
homeopathic drugs experienced more characteristic
symptoms, independent of their group allocation. The
qualitative analysis of the characteristic symptoms
showed a mixed result: there was a wide range of over-
lapping symptoms for both groups, but also qualitative
reporting of symptoms distinguishing Okoubaka from
placebo.
In this study we combined high standards of quantita-
tive trial methodology with qualitative methods. We thus
combined deductive qualitative analysis methods (coding
of characteristic symptoms and proving symptoms) with
modern quantitative statistical analyses to investigate
differences in a HDP between the homeopathic remedy
O. aubrevillei C12 and placebo. We used only highly in-
dividual (characteristic) symptoms as the primary out-
come parameter.
Table 3 Outcomes and subgroup analysis
Placebo Okoubaka aubrevillei
n Characteristic symptoms n Characteristic symptoms Significance of group difference,
adjusted (P value)
Outcome
Characteristic symptoms 11 4.9 (± 5.6) 18 5.4 (± 6.0) 0.843
Proving symptoms 11 9.6 (± 10.6) 18 8.8 (± 9.6) 0.951
Subgroup analysis
Gender
Male 3 2.3 (± 3.2) 7 2.3 (± 2.8)
Female 8 5.9 (± 6.2) 11 7.5 (± 6.7)
Age
<35 years 3 4.7 (± 5.6) 13 5.2 (± 5.5)
≥35 years 7 4.4 (± 6.2) 5 6.2 (± 7.6)
Sensitivity (subjects’ estimation)a
- Strong reaction / reaction 11 4.9 (± 5.6) 10 5.8 (± 6.7)
- Slight reaction / no reaction 0 0 7 4.7 (± 5.7)
Sensitivity (investigators’ estimation)
- Strong reaction / reaction 10 5.4 (± 5.7) 15 6.3 (± 6.2)
- Slight reaction / no reaction 1 0 2 1.0 (± 1.4)
Expected reaction to homeopathic drug (subjects’ estimation)
- Very high number / many symptoms 4 8.0 (± 7.0) 2 1.5 (± 2.1)
- Low number / no symptoms 7 3.1 (± 4.2) 15 5.9 (± 6.3)
Expected reaction to homeopathic drug (investigators’ estimation)
- Very high number / many symptoms 9 6.0 (± 5.7) 10 7.5 (± 6.1)
- Low number / no symptoms 2 0 7 3.0 (± 5.4)
Characteristic symptoms presented as mean ± standard deviation. aOne subject did not rate his expectations.
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study is the combination of a qualitative with a quantita-
tive analysis. It discriminates characteristic symptoms
from more usual symptoms, allowing a more precise
quantitative analysis, but its quality has, on the contrary,
a strong impact on the quantitative results. In our trial
the results depended on the coding of two homeopaths,
both of them with long-term experience in HDPs. The
inter-coder reliability showed a Cohen’s kappa of 0.69.
The common standard for a good quality of coding is
0.7. This is the first time inter-coder reliability was cal-
culated in an HDP, and resulted in an acceptable level of
concordance between the two coding homeopaths.
Another limitation is the unbalanced randomisation
allocation, resulting in a significant difference in num-
bers of included subjects between Okoubaka and con-
trol. This imbalance was due to the block-randomisation
design stratified by the centre and to some centres only
including one or two subjects. This presents a problem
for the qualitative analysis, because the range of poten-
tial characteristic symptoms in the placebo can be esti-
mated to be smaller in 12 subjects compared with 19subjects in the Okoubaka group: more individuals could
show a wider range of individual symptoms.
The bark of the West African rainforest tree O.
aubrevillei was introduced into homeopathy in the
1970s by the homeopathic physician Magdalena Kunst
and the pharmacist Wilmar Schwabe, who discovered
that Okoubaka bark was used by native African healers
against food poisoning. O. aubrevillei is a registered
homeopathic drug in Germany and is mainly used for
the treatment of symptoms of gastrointestinal distur-
bances, food poisoning and food allergies [16-19]. A
former HDP of O. aubrevillei was conducted by David
Riley [20]. The comparison of the symptom profiles of
Okoubaka and placebo groups with the results of the
former proving and the clinical use remains inconclu-
sive: there is a high overlap of symptoms throughout all
groups but there are also symptoms overlapping only
between the Okoubaka group and the results of the earl-
ier proving and the clinical profile (compare Table 4).
In our trial there is a notably high number of charac-
teristic symptoms in both groups. Characteristic symp-
toms are by definition symptoms individualising the
Table 4 Qualitative symptom profiles of intervention and control groups, former homeopathic drug proving and clinical use
Placebo (control) Okoubaka aubrevillei C12
(intervention)
Symptoms only observed in
Okoubaka group
Profile of O. aubrevillei from
former homeopathic drug
proving [20]
Profile of clinical use of
O. aubrevillei [19]
Mind Tranquillity and calmness, feels
content although being in trouble,
ability to reflect on things from a
different perspective.
Concentration deficiency, confusion,
disorientation, feeling as if ‘head like
in cotton’, ‘like under a bell’, ‘as if
drunk’, helplessness, sadness.
Oversights, being at loss of words,
things fall from the hands, slowing
down, fatigue, tiredness, weakness.
Irritability, impatience, helplessness,
sadness.
Irritability improves or increases.
Discouraged and feeling of being
incompetent.
Irritable. Angry. Aggressive and
depressive (aggravated before
menses), cannot suffer himself,
cannot cry. Ambitious, stingy.
Concentration weak after
influenza/viral infection.Senses acute, senses of smell,
hearing of voices increased, vision
more clear.
Calmness with stressful emotional
situation.
Tiredness in the day and evening. Irritability, feeling of mental
overload, desire for rest. Impatience.
Fears of aging and poverty.
Desire to chew and bite his own
inner cheek.Being at loss for words,
concentration deficiency, being
disorganised, not able to think
clearly, feeling of standing beside
himself. Mistakes in writing and
problems in calculating.
Improved concentration.
Head Strong cephalalgias, heading on
from the nape outgoing, on both
sides, more prominent on the left
side, vaguely oppressive, bonnet-like
pain from the inside outwards.
Aggravated after awakening, the
sun, warmth, motoring, beginning
of the menses. Ameliorated at 3 p.
m., by lying with supported nape,
deviance.
Oppressive pains behind eyes and
forehead and temples, move to the
back of the head. Foggy brained
feeling of head. Nausea and loss of
appetite. Amelioration by rest, lying,
pressure on eyes; aggravation in
standing position, walking. Suction-
like feeling from the skull cap down
to the right side and dizziness.
Foggy brained feeling of head.
Headaches and nausea. Suction-like
feeling from the skull cap down to
the right side.
Congestion in head. Pressure at
vertex. Pressure over the left temple
as if in a vice.
Awakening at 5 am by
cephalalgias. Migraine. Eczema
of the scalp. Alopecia.
Cephalalgias with pain rising up
from the nape of neck to the back
of the head, and at the same time
to the forehead, pulsating and
knocking pain in right hemisphere,
stitching. Wave-like pulsations,
aggravated 12 to 3.30 p.m., in the
evening, with beginning of menses,
motion; ameliorated by rest, at 4 to
6 p.m. Photosensitivity. Feeling of
pressure to eyeballs.
Cephalalgias, oppressive, like band
feeling around temples, like a nail in
the forehead, as if a knife stitches in
nasal root and from nasal septum
downwards. Feeling of pressure in















Table 4 Qualitative symptom profiles of intervention and control groups, former homeopathic drug proving and clinical use (Continued)
Rotary vertigo in the evening,
ameliorated while sitting, with
sweating and frost feeling in legs.
Eyes Dryness, sandy feeling, allergic
oculorhinitis.
Dryness, sandy feeling, allergic
oculorhinitis.
Swelling beneath the eye. Watery
and itching eyes as if allergy season.




Ears Oozing, itchy exanthema behind
the ears.
Oozing, itchy exanthema behind
the ears.
Tinnitus, ear pains, deafness.
Nose Allergic coryza, itching, running or
blocked nose, yellow and viscous to
liquid mucous, nosebleed.
Allergic coryza, itching, running or
blocked nose, yellow and viscous to
liquid mucous, nosebleed.
Epistaxis from right nostril. Chronic sinusitis. Allergic
rhinitis.
Nasal discharge that is clear like
with allergy. Sneezing. Aching and
burning sinuses.
Face Redness and sensations of heat,
soreness, dryness, burning.
Sensations of soreness, dryness,
burning.
Fever blister on lower lip. Herpes labialis.
Mouth/
Throat
Dryness feeling. Metallic taste.
Aphthae.
Feeling of soreness, dryness,
redness of the mucosa, chronic
pharyngitis with vesicles and wheals
(lasting for 6 months), difficulties in
swallowing, ameliorated by drinking
of hot drinks and eating food, warm
foods.
Pharyngitis with vesicles and
wheals.
Aphthae on tongue and lower lip
that are painful. Boils on the gums.
An odour like rotten meat
originating from the throat.
Aphthae. Tongue whitish [?],
with dental impressions.
Suppurations of roots of teeth.




Teeth: pulling pains at incisors, pain
of molars in the root area,
ameliorated with warm foods and
drinks.
Changed taste of foods. Boils in mouth with a rotten meat
odour coming from throat
Neuralgic pain of upper and lower
tooth row on the right side.
Corrosive burning ‘as if burning
liquid runs down the pharynx’,
rough scratching, constrictive
feeling of throat.
Scratching sore throat on
swallowing.
Lymph nodes at neck swollen.
greenish–brown–yellowish sputum.
Changed taste of foods. Dry lips,
burning sensations. Whitish fur on
tongue.
Stomach Slack feeling in the stomach,
nausea.
Nausea and cephalalgias, loss of
appetite, aggravated by thinking of
food, ameliorated by eating.
Nausea and cephalalgias,
aggravated by thinking of food.
Feeling of pressure on stomach.
Nausea after eating or on waking.
Sour stomach and burning during
the night. Weakness with vomiting.
Feeling as if a stone is lying in
the stomach, ameliorated by
warm drinks. Feeling of
sickness in the morning, with
teeth brushing. Vomiting.Feeling of pressure on stomach,
piercing, hard, cramping sensation.
Aggravation in the evening, by
belching, eating and drinking.
Amelioration by eating.
Abdomen Pains in the lower abdomen,
spasmodically with flatulence.
Oppressive pains, ‘as if hand around
stomach’. Pains in the right
epigastrium. Fist-like starting point
Oppressive pains, ‘as if hand around
stomach’. Pains in the right
epigastrium. Fist-like starting point
Pain in general. Cramping pain.
Cramping pain better bending over

















Table 4 Qualitative symptom profiles of intervention and control groups, former homeopathic drug proving and clinical use (Continued)
of pain in the area of the cholecyst,
oppressive, pulling sensation of
pain. Amelioration by raising, sitting
and stretching. Aggravation by
stooped seats.
of pain in the area of the cholecyst,
oppressive, pulling sensation of
pain. Amelioration by raising, sitting
and stretching. Aggravation by
stooped seats.




food. Thin, bright, sharply
smelling stools.Offensive flatus in evening. Stabbing
pains during bowel movements.
Diarrhoea.
Urinary tract Burning in the urethra, aggravated
by urination.




Monthly period with increased
bleeding.
Monthly period too early or too
late. Dysmenorrhoea with
spasmodic pains. Stitching and
tense pain of the breasts before
menses.
Monthly period too early or too
late. Dysmenorrhoea with
spasmodic pains. Stitching and
tense pain of the breasts before
menses.
Delayed menses. Short menses. Irregular bleedings between
menses, premenstrual breast
pain.Increased sexual desire after menses.
Respiration,
chest, heart
Cough, spasmodically with choking.
Aggravated in lying. Sharp, strong
pain of right rib curves in the
axillary line, aggravated in the
morning with the awakening,
ameliorated by getting up, walking
around, external pressure, massage.
Inhaling is difficult.
Palpitations. Pulsations. Pressure
feeling and narrow feeling on
thorax: ‘As if something heavy lies
on the chest’. Burning and heat
feeling behind sternum. Aggravated
by lying on the left side, by drinking
green tea, emotional strain.
Palpitations. Pulsations. Pressure
feeling and narrow feeling on
thorax: ‘As if something heavy lies
on the chest’. Burning and heat
feeling behind sternum. Aggravated
by lying on the left side.
Bronchial itch with cough. Allergic rhinitis, asthma.
Sensation as if lungs overexpanded.
Back Gluteal pains on the left side,
pulling, oppressive, emitting to left
femur, aggravated in the mornings,
at noon, while sitting, with walking,
distension, pressure, driving car.
Myalgias in the shoulder nape area,
burning pain, ameliorated by
stretching. Pain in the ileosacral
area, aggravated by long sitting,
standing position, ameliorated by
warmth and motion. Sudden
clinching back pains in the
crossings of TH 12 to L1, mixture of
pressure and blockade, ameliorated
by motion, bathing feet in the sea,
aggravated by sitting and lying.
Burning myalgias, ameliorated by
warmth.
Pain at left lower abdomen,
ameliorated by position change.
Pains lumbar vertebra column and
ileosacral, on the right side,
stitching, oppressive, ameliorated by
bending forward.
Extremities Knee pain on the left, aggravated
by motion, climbing down stairs.
Feeling of distortion and pains in
wrists and ankle joints, as if swollen,
ameliorated by motion.
Pains and cracks in the knee joint.
Sensitive soles. Myalgias, cramps.
Feeling of heaviness, drawing,
soreness in muscles. Tired feelings.
Myalgias, cramps. Feeling of
heaviness, soreness in muscles.
Tired feelings.
Aching ankle pain or improvement
of aching foot arches. Foot pain.
Right knee displacement during
sleep causing the tendons to draw
up the leg. Aching of calf extending
from ankle to knee better stretching.
Oedemas of the fingers and
ankles. Pain in finger joints.
Thumb joint arthrosis.
Sleep Fatigue with the awakening, night
awakening.
Fatigue with the awakening, night
awakening.
Sleep disrupted by waking for
extended times.
Tiredness, desire to sleep.















Table 4 Qualitative symptom profiles of intervention and control groups, former homeopathic drug proving and clinical use (Continued)
Skin Vesicular eczema of the hands. Dryness of the skin. Warts, small
pinhead-like warts in soles.
Dryness of the skin. Warts, small
pinhead-like warts in soles.
Itchy skin. Eczemas and exanthemas





Flushes of heat and increased
sweating.
Coldness, freezing. Need for
warmth, feverish sweating.
Appetite Appetite decreased, increased. Desire for warm food. Desire for warm food.
Thirst Decreased thirst feeling. Dryness of mouth, desire for warm
drinks.
Desire for warm drinks.
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stand out to the subjects both in quality and intensity,
and have not been experienced in quality or intensity by
subjects before. Most of our subjects observed patho-
logical symptoms that were different from their usual
complaints.
Interestingly, female subjects described characteristic
symptoms much more frequently than male subjects.
Gender differences in HDP have been highlighted previ-
ously. In the 1980s, Stübler observed in his scientific
HDP that female subjects had more proving symptoms
than males [21].
In our opinion, the results must be interpreted with
care and we want to discuss hypothetical explanations.
The profiles of symptoms in both groups show a sur-
prisingly high number of characteristic symptoms. One
might argue that these cannot be explained by
nonspecific effects alone. In our trial, the characteristic
symptoms in both groups were compared qualitatively
and subsequently compared with the clinical profile of
O. aubrevillei. A range of similarities was observed.
Similarities in symptom profiles between groups proving
homeopathic drug and placebo have already been
reported by homeopaths in the past. Jeremy Sherr, who
actively re-established HDPs in the 1980s and 1990s,
writes in his manual The Dynamics and Methodology of
Homeopathic Provings: ‘. . . Furthermore it is interesting
to note that placebo proving occasionally seem to pro-
duce similar symptoms to the proving symptoms, thus
casting further doubt on the use of this medium in prov-
ing’ [22]. Walach observed in two more recent HDPs
(Atropa belladonna, and Cantharis) symptoms that were
considered highly specific for the homeopathic drug also
in the placebo group [8,10,23]. However, these results
were in contrast to another homeopathic proving, where
a specific effect was observed [9]. It is plausible that the
results of this trial may be explained by the nocebo ef-
fect. The nocebo effect is by definition the induction of
a symptom perceived as negative by sham treatment
and/or by the suggestion of negative expectations [24].
A nocebo response is induced by the subject’s own nega-
tive expectations and/or negative suggestions from ther-
apists/clinical staff in the absence of any treatment.
Nocebo phenomena are generally explained by Pavlovian
conditioning and expectations induced by verbal infor-
mation and suggestions [24]. In our trial this would
mean that there were no specific drug effects at all: sub-
jects experienced nonspecific nocebo symptoms regard-
less of group allocation. The specific, individual and new
symptoms in the qualitative analysis might be explained
by expectation, suggestion and conditioning of the sub-
jects or just by chance. The observation that subjects
with a high expectation of being sensitive to homeo-
pathic drugs experienced more characteristic symptomsregardless of group allocation would fit this hypothesis.
Expectation, former experiences and intensified aware-
ness would explain the development of characteristic
symptoms in both groups. Nocebo has only recently re-
ceived wider attention from scientists and clinicians and
the available data are sparse compared with research
about placebo phenomena [24]. Sex has recently being
discussed as a predictor for nocebo response. In a study
with healthy subjects measuring symptoms of nausea
caused by a spinning chair, gender differences were
found: nausea could be conditioned to a significantly
higher degree in women, whereas the effects of expect-
ancy were more prominent in men, but to a lesser de-
gree [24,25]. It is also known from nocebo research that
patients specify more adverse effects of their medication
when checking off a standardised list of symptoms com-
pared with being asked to report spontaneously [26].
Moreover, the way in which trials record adverse events
influences the rate of adverse reactions substantially.
This might have been the case in our trial, which used
semistructured head-to-feet documentation online to be
filled with free text symptom descriptions by subjects.
The phenomenon of developing homeopathic proving
symptoms under placebo has already been described.
Bayr stated in 1986 in The British Homeopathic Journal:
‘The type of change observed during homeopathic drug
trials can also be noted following exhibition of placebo.
This makes it more difficult to evaluate the results of
homeopathic drug tests’ [27]. Bayr proposed to weight
symptoms for the statistical analysis according to their
homeopathic symptom characteristics. In our analysis
we did not follow Bayr’s advice but we used qualitative
methods to eliminate noncharacteristic symptoms for
the primary statistical analysis. Therefore our outcome
parameter is highly concordant with the homeopathic
philosophy. However, we found no statistical group
differences.
Another explanation might be that the nocebo
response is so prominent that potentially specific symp-
toms of the drug are difficult to observe and are hidden
behind a strong background noise. If this hypothesis was
true, the nocebo response as background noise would
strongly disturb any HDP and would make it extremely
difficult to identify specific symptoms. However, by using
a qualitative approach to identify only homeopathic
characteristic symptoms, our analysis attempted to filter
out such background noise.
Nocebo responses are also frequently observed as
adverse events in the placebo arm of randomised con-
trolled drug trials and are known to be a confounding
factor in clinical drug trials. In migraine trials, for
example, they are observed in 20% of patients after pla-
cebo treatment [28]. They also account substantially for
adverse events in drug trials for fibromyalgia syndrome
Teut et al. Trials 2013, 14:96 Page 12 of 13
http://www.trialsjournal.com/content/14/1/96and painful diabetic peripheral neuropathy [29]. Surpris-
ingly, the observed adverse events in placebo arms of tri-
als with anti-migraine medication corresponded to those
of the anti-migraine medication against which the pla-
cebo was compared; the same is the case with nocebo
symptoms in antidepressant trials [30]. Nocebo symp-
toms reflect the typical side effects pattern expected in
the drug group, being in accordance with the expect-
ation theory of placebo and nocebo effects [31]. Link
and colleagues reported a sham herbal trial where 36
healthy college students were informed they would be
given either a herbal supplement or a placebo and were
provided with an information sheet with a mock list of
possible beneficial (for example, cognitive enhancement)
and adverse effects of the supplement, but in fact all par-
ticipants received placebo [32]. Thirty-two of the 36 par-
ticipants (88.9%) reported symptoms following ingestion
of the pill (50% placebo symptoms, 27.8% placebo and
nocebo symptoms, 11.1% only nocebo symptoms). The
most frequently observed placebo symptoms were
clearer thinking (61.1%) and increased mental alertness
(52.8%), and the most frequently observed nocebo symp-
toms were dry mouth (22.2%), fatigue (16.7%) and head-
aches (8.3%). In our trial the expectation to observe
proving symptoms might have been high, as the subjects
were all homeopathic experts and familiar with the con-
cept of HDP.
Conclusions
Combining qualitative and quantitative methods for the
primary outcome did not result in a significant differ-
ence of characteristic symptoms between O. aubrevillei
C12 and placebo. The qualitative comparison of the
symptom profiles leaves some open questions. The
nocebo effect might be a plausible explanation for most
of the phenomena observed in this trial.
Abbreviation
HDP: Homeopathic drug proving.
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